Please login to the form below
Russia
This page shows the latest Russia news and features for those working in and with pharma, biotech and healthcare.
Novartis reports death of two patients treated with Zolgensma
The two fatal cases of acute liver failure – which were seen in children – took place in Russia and Kazakhstan after five to six weeks after administration of Zolgensma.
Latest news
-
Pfizer donates $5m in Russian profits to humanitarian causes amid war in Ukraine
Pfizer concluded that a voluntary pause in the flow of its medicines to Russia, including cancer or cardiovascular therapies, would cause significant patient suffering and potential loss of life, particularly among ... However, the company made the
-
Pfizer highlights need for fourth dose of COVID-19 vaccine to FDA
of excess deaths – compared to the number of deaths that would be expected on the basis of past trends in all-cause mortality – followed by the US and Russia.
-
UK’s Competition and Markets Authority to review AZ/Alexion merger
Competition clearances have also been completed in Canada, Brazil, Russia and other countries.
-
BeiGene, Novartis' tislelizumab report promising topline results in nasopharyngeal cancer
As part of that agreement, Novartis gained development and commercialisation rights to tislelizumab in the US, Canada, Mexico, the EU, UK, Norway, Switzerland, Iceland, Liechtenstein, Russia and Japan for an upfront
-
BeiGene, Novartis’s PD-1 inhibitor tislelizumab hits the mark in second- or third-line NSCLC
As part of that agreement, Novartis gained development and commercialisation rights to tislelizumab in the US, Canada, Mexico, the EU, UK, Norway, Switzerland, Iceland, Liechtenstein, Russia and Japan for an upfront
More from news
Approximately 12 fully matching, plus 211 partially matching documents found.
Latest Intelligence
-
To avoid making mistakes when applying behavioural insights in healthcare, we need to understand why people do what they do
Many countries across the world, including India, Russia, Serbia, Thailand, the UK and the USA have offered cash payments, savings bonds, lottery tickets, tickets to the theatre, sports clubs and local
-
How will COVID-19 affect uptake of vaccinations against other diseases?
Notably, Russia’s Sputnik V vaccine, developed by Moscow’s Gamaleya research centre, and announced by President Vladimir Putin in August as being the world’s first registered coronavirus vaccine, despite
-
Risks, reforms and rewards: the evolving Russian healthcare market
For the pharmaceutical industry, the Russia healthcare sector presents both opportunities and challenges. ... Online pharmaceutical sales may also be a factor in Russia in the next few years.
-
As COVID-19 takes over the world, biopharma fights back
The partners have already initiated trials in the US, as well as in a number of other countries including Italy, Spain, Germany, France, Canada and Russia.
-
BRIC markets
Economists started grouping Brazil, Russia, India and China (BRIC) together in the early 2000s based on predicted GDP growth rates. ... In addition the authors wrote: ‘Financing for drug provision in Russia is divided into two levels: federal and
More from intelligence
Approximately 7 fully matching, plus 44 partially matching documents found.
Latest appointments
-
Bo Jesper Hansen to step down as chairman of Sobi
and Russia”. ... Björklund served as chief executive officer at Nycomed until 2011 and oversaw its growth from a largely Scandinavian business into a global pharmaceutical company operating across Europe, Latin America and Russia.
-
Lupin appoints Thierry Volle president for EMEA
Volle will be responsible for the company's growth and development in Europe, Russia and CIS, as well as the Middle-East and African markets, and he will be based at
-
Dr Maurice Chagnaud appointed as new CEO of Polpharma
He will join the company next week from Lupin where he was a group president with an inhalation remit for Europe, Russia &CIS. ... Polpharma operates across Europe, CIS and Central Asia and has manufacturing subsidiaries in Poland, Russia and Kazakhstan.
-
EMA appoints Luc Vanheel as head of administration
Throughout his career, Vanheel has lived and worked in seven countries including Russia, Japan, Croatia, Belgium and Germany.
-
New CEO for Grayling Germany
Frank is an exceptional talent and we are very proud to have him on board,” said Jan Simunek, Grayling's regional director for the DACH region, Central &Eastern Europe, Russia and
More from appointments
Approximately 1 fully matching, plus 10 partially matching documents found.
Latest from PMHub
-
Innovative Trials suspends services in Russia in response to Ukraine war
Kate Shaw, Founder &CEO of the leading patient recruitment organisation based in Letchworth (UK), on the current Russia-Ukraine situation. ... Innovative Trials, the leading patient recruitment organisation, has suspended all services in Russia and had
-
M3 Acquires MirVracha LCC in Russia Launching Full-Scale Development of Physician Platform Business in Russia
M3, Inc. (Headquarters: Tokyo, Japan; CEO: Itaru Tanimura; URL: https://corporate.m3.com/; “M3” below) has announced the acquisition of MirVracha LCC (Headquarters: Moscow, Russia; CEO: Shotaro Yamamoto; “MirVracha” below), a ... that MirVracha
-
Innovative Trials
Innovative Trials suspends services in Russia in response to Ukraine war. ... Kate Shaw, Founder &CEO of the leading patient recruitment organisation based in Letchworth (UK), on the current Russia-Ukraine situation.
-
M3 (EU)
M3, Inc. (Headquarters: Tokyo, Japan; CEO: Itaru Tanimura; URL: https://corporate.m3.com/; “M3” below) has announced the acquisition of MirVracha LCC (Headquarters: Moscow, Russia; CEO: Shotaro Yamamoto; “MirVracha” below), a ... that MirVracha
-
Clinical and Diagnostics Center
We collaborate with foreign companies from the France, Germany, USA, Great Britain, Switzerland, Spain, Sweden, Poland, Latvia, Croatia, Russia.
More from PMHub
Approximately 1 fully matching, plus 23 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Country Manager, Healthcare Communications Agency, Germany
-
Highly competitive salary
- Sanofi halts recruitment for trials assessing MS treatment
- Environment: where does the pharmaceutical industry stand?
- bluebird bio reveals plans to launch two gene therapies
- Novartis reports death of two patients treated with Zolgensma
- ONS data reveals significant decrease in COVID-19 antibodies
- AstraZeneca and Daiichi Sankyo receive FDA approval for lung cancer drug
- Are we the masters or servants of omnichannel engagement?
- JCVI publishes advice on COVID-19 vaccines ahead of autumn booster campaign
- AstraZeneca and Daiichi Sankyo’s Enhertu shows significant improvement for breast cancer patients
- Gilead Sciences announce positive results for Trodelvy in breast cancer patients
- UK government to launch national mission to tackle dementia
- WHO publishes first position paper on optimising brain health
- Amgen acquires ChemoCentryx in $3.7bn cash deal
- Sanofi halts recruitment for trials assessing MS treatment
- AstraZeneca and Daiichi Sankyo announce results for lung cancer therapy
- JCVI publishes statement on London polio vaccination strategy
- Low-dose LSD looks safe for Alzheimer’s patients, but will it work?
- Michael J Fox Foundation awards Koneksa second research grant
PMHub
Porterhouse Medical Group
The Porterhouse Medical Group provides powerful, insight-driven, healthcare communication services to the pharmaceutical industry across the globe, with a focus...
Latest intelligence
- Environment: where does the pharmaceutical industry stand?
- ...
- The communication challenge of helping he next generation to be healthier
- As the pressure on the health service increases the health of the next generation is vital for everyone. How do we show positive attitudes and change behaviour while future proofing...
- Are we losing sight of what the democratisation of healthcare really looks like?
- We have a core responsibility as healthcare communicators to consistently drive for better inclusion, engagement and compliance. What does the ‘democratisation of healthcare’ really look like?...
